@entity6 @entity1 have a markedly increased risk of @entity65 compared with non-diabetics. Two drug groups today target insulin resistance; @entity37005 and @entity12721 . In addition, these may have other effects on cardiovascular risk factors. The aim of this study was to evaluate the effects of @entity2449 and @entity6170 on non-traditional cardiovascular risk factors. Forty @entity164 2 @entity6 @entity1 were randomized into @entity2449 and @entity6170 groups. After receiving the optimal doses, the @entity1 were monitored for 12  weeks. Biochemical parameters, lipid parameters, @entity2690 , and HbA1c levels were analyzed. @entity2881 , @entity2289 , @entity2071 , @entity310 , @entity650 , @entity4105 , and fibrinogen levels were measured in order to assess coagulation status and @entity409 . In the @entity2449 group, body mass index, @entity2017 , HbA1c, @entity650 , @entity2071 , and @entity310 levels were significantly decreased after 12  weeks compared with the basal levels. @entity650 levels decreased from 75  pg/ml      20 to 42  pg/ml      9 (P 0.023) and @entity310 levels from 61  pg/ml      31 to 39  pg/ml      10 (P 0.018). In the @entity6170 group, FPG, @entity2017 , HbA1c, insulin, HOMA-IR, @entity650 , and @entity310 levels decreased significantly after 12  weeks compared with the basal levels. @entity650 levels decreased from 78  pg/ml      21 to 41  pg/ml      9 (P 0.028) and @entity310 levels from 62  pg/ml      19 to 37  pg/ml      10 (P 0.012). At the end of the study, no significant differences were determined between groups. Insulin resistance and @entity164 2 @entity6 are strongly associated with low grade @entity32 . Both @entity2449 and @entity6170 were effective in controlling inflammatory markers in addition to metabolic parameters.

The effects of @entity6170 and @entity2449 on XXXX and @entity409 in @entity1 with @entity6 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity2289 :: ('5054', 'Gene') :: ['PAI-1'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'Diabetic', 'diabetes'] @entity310 :: ('7124', 'Gene') :: ['TNF-a', 'TNF- a'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity37005 :: ('MESH:D001645', 'Chemical') :: ['biguanides'] @entity2690 :: ('3630', 'Gene') :: ['CRP, insulin, c-peptide'] @entity2017 :: ('5552', 'Gene') :: ['PPG'] @entity4105 :: ('6401', 'Gene') :: ['E-selectin'] @entity12721 :: ('MESH:D045162', 'Chemical') :: ['thiazolidinediones'] @entity2881 :: ('7450', 'Gene') :: ['VWF'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity2071 :: ('3383', 'Gene') :: ['ICAM-1'] @entity6170 :: ('MESH:C089730', 'Chemical') :: ['rosiglitazone'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity32 :: (MESH:D007249,Disease) :: ['inflammation']
